Vascular endothelial growth factor-2: Final Phase IIb data

Final data from the double-blind, dose-ranging U.S. Phase IIb GENASIS trial showed that VEGF-2 gene therapy missed the primary endpoint of an improvement of at least 1 minute in ETT at 90 days. VEGF a...